Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPOR | P19235 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | CETP | P11597 | 6/20 | 0.49 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515961 | 0.84 | SMN1; SMN2 (0.62) | EPORSMN1; SMN2NR3C1ALDH1A1 | |
| SCHEMBL9795739 | 0.84 | EPOR (0.51) | EPORSMN1; SMN2AKR1C3DAGLAERCC5 | |
| SCHEMBL342248 | 0.83 | LMNA (0.54) | — | |
| SCHEMBL340808 | 0.82 | CRHBP (0.47) | ALDH1A1 | |
| SCHEMBL516646 | 0.82 | EPOR (0.40) | EPORSMN1; SMN2CETPDAGLA | |
| SCHEMBL17975523 | 0.78 | MTNR1A (0.52) | — | |
| SCHEMBL202173 | 0.78 | TDP1 (0.50) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL1025218 | 0.77 | KMO (0.44) | CETPERCC5FEN1HDAC8 | |
| SCHEMBL11735577 | 0.77 | ALDH1A1 (0.55) | SMN1; SMN2CETPKDM4EALDH1A1 | |
| SCHEMBL14611444 | 0.77 | PLA2G2A (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046739-B1 | SUBSTITUTED ANILINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2046739-B1 | SUBSTITUTED ANILINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2015-08-26 | — | — | EP | disclosed |
| US-8624022-B2 | Substituted aniline derivatives | UCB PHARMA, S.A. (BE) | 2014-01-07 | — | — | US | disclosed |
| US-8624022-B2 | Substituted aniline derivatives | UCB PHARMA, S.A. (BE) | 2014-01-07 | — | — | US | disclosed |
| US-8624022-B2 | Substituted aniline derivatives | UCB PHARMA, S.A. (BE) | 2014-01-07 | — | — | US | disclosed |
| US-20120029188-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-20120029188-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-20120029188-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-8071582-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071582-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20110014271-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2011-01-20 | — | — | US | disclosed |
| US-7678785-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2010-03-16 | — | — | US | disclosed |
| US-7678785-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2010-03-16 | — | — | US | disclosed |
| US-7678785-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2010-03-16 | — | — | US | disclosed |
| EP-2046739-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB Pharma S.A. (BE) | 2009-04-15 | — | — | EP | disclosed |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | US | disclosed |
| WO-2008012524-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012524-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029188-A1 | Substituted Aniline Derivatives | NAT1, DPM1, IL4I1 | EPOR 1905/4885SMN1; SMN2 2874/4885AKR1C3 761/4885 |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | DPM1, ERG28, IL4I1 | EPOR 2726/4885SMN1; SMN2 2292/4885AKR1C3 409/4885 |
| US-20110014271-A1 | Substituted Aniline Derivatives | NAT1, DPM1, IL4I1 | EPOR 1905/4885SMN1; SMN2 2874/4885AKR1C3 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.